Get started
Enanta Pharmaceuticals, Inc.Enanta Pharmaceuticals, Inc.Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ENTA chart


Full chart

ENTA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪129.29 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.49 USD
Net income (FY)
‪−116.05 M‬ USD
Revenue (FY)
‪67.64 M‬ USD
Shares float
‪19.73 M‬
Beta (1Y)
1.14

Employees


Employees (FY)
131
Change (1Y)
−14 −9.66%
Revenue / Employee (1Y)
‪516.30 K‬ USD
Net income / Employee (1Y)
‪−885.84 K‬ USD

About Enanta Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Jay R. Luly
Headquarters
Watertown
Website
enanta.com
FIGI
BBG001V9NSB4
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ENTA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ENTA is 6.10 USD — it has decreased by −4.24% in the past 24 hours. Watch Enanta Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Enanta Pharmaceuticals, Inc. stocks are traded under the ticker ENTA.
ENTA stock has fallen by −2.40% compared to the previous week, the month change is a −34.48% fall, over the last year Enanta Pharmaceuticals, Inc. has showed a −32.22% decrease.
We've gathered analysts' opinions on Enanta Pharmaceuticals, Inc. future price: according to them, ENTA price has a max estimate of 21.00 USD and a min estimate of 9.00 USD. Watch ENTA chart and read a more detailed Enanta Pharmaceuticals, Inc. stock forecast: see what analysts think of Enanta Pharmaceuticals, Inc. and suggest that you do with its stocks.
ENTA reached its all-time high on Jul 6, 2018 with the price of 127.77 USD, and its all-time low was 5.70 USD and was reached on Dec 18, 2024. View more price dynamics on ENTA chart.
See other stocks reaching their highest and lowest prices.
ENTA stock is 11.17% volatile and has beta coefficient of 1.14. Track Enanta Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Enanta Pharmaceuticals, Inc. there?
Today Enanta Pharmaceuticals, Inc. has the market capitalization of ‪129.28 M‬, it has increased by 3.92% over the last week.
Yes, you can track Enanta Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Enanta Pharmaceuticals, Inc. is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
ENTA earnings for the last quarter are −1.36 USD per share, whereas the estimation was −1.16 USD resulting in a −17.17% surprise. The estimated earnings for the next quarter are −1.35 USD per share. See more details about Enanta Pharmaceuticals, Inc. earnings.
Enanta Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪14.61 M‬ USD, despite the estimated figure of ‪17.93 M‬ USD. In the next quarter, revenue is expected to reach ‪17.25 M‬ USD.
ENTA net income for the last quarter is ‪−28.82 M‬ USD, while the quarter before that showed ‪−22.66 M‬ USD of net income which accounts for −27.21% change. Track more Enanta Pharmaceuticals, Inc. financial stats to get the full picture.
No, ENTA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 131.00 employees. See our rating of the largest employees — is Enanta Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Enanta Pharmaceuticals, Inc. EBITDA is ‪−119.36 M‬ USD, and current EBITDA margin is −176.47%. See more stats in Enanta Pharmaceuticals, Inc. financial statements.
Like other stocks, ENTA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enanta Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enanta Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enanta Pharmaceuticals, Inc. stock shows the sell signal. See more of Enanta Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.